Relmada Therapeutics (RLMD)
4.43
+0.06 (1.37%)
Upcoming Events
Latest Headlines
Form SCHEDULE 13G/A RELMADA THERAPEUTICS, Filed by: Squadron Capital Management LLC
August 14, 2026 1:18 PM - SEC Filing
Mizuho sees a chance to buy this biotech stock after recent weakness
August 14, 2026 1:00 PM - StreetInsider
Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD)
August 11, 2026 5:10 AM - StreetInsider
Relmada Therapeutics (RLMD) Tops Q2 EPS by 8c
August 6, 2026 5:05 PM - StreetInsider
Form 8-K RELMADA THERAPEUTICS, For: Aug 06
August 6, 2026 4:44 PM - SEC Filing
Form 10-Q RELMADA THERAPEUTICS, For: Jun 30
August 6, 2026 4:20 PM - SEC Filing
Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 6, 2026 4:05 PM - Globe NewsWire
Form SCHEDULE 13G RELMADA THERAPEUTICS, Filed by: BlackRock, Inc.
July 29, 2026 3:22 PM - SEC Filing
Form 8-K RELMADA THERAPEUTICS, For: Jul 28
July 28, 2026 8:36 AM - SEC Filing
Relmada Therapeutics names Bipin Dalmia as chief business officer
July 28, 2026 8:31 AM - StreetInsider
Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer
July 28, 2026 8:30 AM - Globe NewsWire
Buy this healthcare stock on weakness: Mizuho
July 23, 2026 2:00 PM - StreetInsider
Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
July 16, 2026 7:05 AM - Globe NewsWire
Relmada Therapeutics added to Russell 2000 and Russell 3000 indexes
June 29, 2026 7:02 AM - StreetInsider
Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes
June 29, 2026 7:00 AM - Globe NewsWire
H.C. Wainwright Reiterates Buy Rating on Relmada Therapeutics Inc (RLMD)
June 23, 2026 6:50 AM - StreetInsider
Form SCHEDULE 13G RELMADA THERAPEUTICS, Filed by: MILLENNIUM MANAGEMENT LLC
June 22, 2026 5:33 PM - SEC Filing
Form S-8 RELMADA THERAPEUTICS,
June 18, 2026 4:06 PM - SEC Filing
H.C. Wainwright Starts Relmada Therapeutics Inc (RLMD) at Buy, PT $12
June 18, 2026 5:59 AM - StreetInsider
Relmada appoints Michael Quirk as senior advisor for sepranolone program
June 11, 2026 7:02 AM - StreetInsider
Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program
June 11, 2026 7:00 AM - Globe NewsWire
Form SCHEDULE 13G RELMADA THERAPEUTICS, Filed by: Venrock Healthcare Capital Partners III, L.P.
June 9, 2026 8:04 PM - SEC Filing
Full Article List
